BTG plc (BTG) Rating Reiterated by Numis Securities Ltd
BTG plc (LON:BTG)‘s stock had its “buy” rating reissued by equities research analysts at Numis Securities Ltd in a report released on Tuesday. They presently have a GBX 900 ($11.24) target price on the stock. Numis Securities Ltd’s target price would indicate a potential upside of 46.10% from the stock’s current price.
Several other research firms have also recently weighed in on BTG. Deutsche Bank AG restated a “buy” rating on shares of BTG plc in a report on Friday, October 7th. Stifel Nicolaus upgraded BTG plc to a “buy” rating and raised their price target for the company from GBX 640 ($8.00) to GBX 725 ($9.06) in a report on Thursday, November 3rd. JPMorgan Chase & Co. raised their price target on BTG plc from GBX 790 ($9.87) to GBX 830 ($10.37) and gave the company a “neutral” rating in a report on Friday, October 7th. Finally, Royal Bank Of Canada cut BTG plc to a “sector performer” rating and dropped their target price for the stock from GBX 910 ($11.37) to GBX 790 ($9.87) in a report on Tuesday, November 1st. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of GBX 820 ($10.24).
Shares of BTG plc (LON:BTG) opened at 612.25 on Tuesday. The stock’s market capitalization is GBX 2.34 billion. BTG plc has a 52 week low of GBX 554.97 and a 52 week high of GBX 739.50. The company has a 50-day moving average price of GBX 661.45 and a 200 day moving average price of GBX 649.86.
About BTG plc
BTG plc is engaged in the business of healthcare, focusing on Interventional Medicine therapies for liver cancer, emphysema and vascular disorders, specialty pharmaceuticals for acute care uses, and a licensing business. The Company operates through three segments: Interventional Medicine, Specialty Pharmaceuticals and Licensing.
Receive News & Stock Ratings for BTG plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BTG plc and related stocks with our FREE daily email newsletter.